Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Complete title: APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
| APEC1621SC |
| Navin Pinto, MD |
| II |
Look up trial at NIH
Research Study Description
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Eligibility Criteria (must meet the following to participate in this
study)
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
| APEC1621SC |
| Advanced Therapeutics Study Line |
| 206/987-2553 |
|
Central Nervous System (CNS); Lymphoma; Lymphoma, Non-Hodgkin (NHL); Sarcoma; Immune System Diseases; Neoplasms, Soft Tissue
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.